BFM
MRKR icon

Boothbay Fund Management’s Marker Therapeutics MRKR Stock Holding History

Boothbay Fund Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-4,555
Closed -$361K – 853
2019
Q2 		$361K Buy
4,555
+604
+15% +$35.9K 0.03% 497
2019
Q1 		$261K Buy
3,951
+1,228
+45% +$71.7K 0.03% 541
2018
Q4 		$151K Buy
+2,723
New +$198K 0.02% 516

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Boothbay Fund Management's MRKR Position: Q3 2019 in Review

Boothbay Fund Management sold out of Marker Therapeutics (MRKR) in Q3 2019, closing a stake of 4,555 shares — an estimated $361K sold.

Boothbay Fund Management first reported a position in MRKR in Q4 2018 and held it in 3 quarters. The position peaked at $361K in Q2 2019. 73 funds tracked by Wall St. Rank hold MRKR as of Q3 2019.

  • Boothbay Fund Management reported no remaining Marker Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Boothbay Fund Management sold 4,555 Marker Therapeutics shares in Q3 2019, an estimated $361K.
  • Boothbay Fund Management first reported a position in Marker Therapeutics in Q4 2018 and held it in 3 quarters.
  • Boothbay Fund Management's Marker Therapeutics position peaked at $361K in Q2 2019.
  • 73 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2019.

Based on Boothbay Fund Management's 13F filing for Q3 2019, filed 14 Nov 2019.